A particle comprising a first fraction containing an active ingredient and a second fraction containing a surfactant, and having a number average particle diameter of from 1 to 100 nm.

To provide a packaging body for a patch exhibiting excellent temporal stability of a drug, a patch product equipped with the patch and a packaging bag, and a method of manufacturing the patch product.

A patch product equipped with a packaging bag formed of a laminate composed of at least three or more layers including a cyclic polyolefin film and a lidocaine- or rivastigmine-containing patch housed in the packaging bag, a method of the patch product, and a packaging body for a patch formed of a laminate including a cyclic polyolefin film.

The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT.sub.2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D.sub.1 and D.sub.2 receptor signaling system, and/or the μ-opioid receptor.

The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT.sub.2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D.sub.1 and D.sub.2 receptor signaling system, and/or the μ-opioid receptor.

Provided are methods of treatment for tumors. In particular, methods are provided for use of a chemically modified IL-10 to treat tumors.

Disclosed are devices, methods and surgical procedures for detecting, imaging, analyzing, diagnosing and/or treating vascular disorders and related conditions of the human and mammalian body in males and/or females. In particular embodiments, treatments include methods for imaging, analyzing and improving erectile dysfunction and related conditions and potentially increasing angiogenesis in response to specifically diagnosed conditions.

Disclosed are devices, methods and surgical procedures for detecting, imaging, analyzing, diagnosing and/or treating vascular disorders and related conditions of the human and mammalian body in males and/or females. In particular embodiments, treatments include methods for imaging, analyzing and improving erectile dysfunction and related conditions and potentially increasing angiogenesis in response to specifically diagnosed conditions.

Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.

Described herein are compounds, compositions, kits, methods, and the uses thereof for treating diseases caused at least in part by virus infection.

The present disclosure relates to lipoprotein complexes and lipoprotein populations and their use in the treatment and/or prevention of dyslipidemic diseases, disorders, and/or conditions. The disclosure further relates to recombinant expression of apolipoproteins, purification of apolipoproteins, and production of lipoprotein complexes using thermal cycling-based methods.